Mdxhealth To Release Third Quarter 2025 Financial Results On November 12
|   Title:  |   Mdxhealth Presents Third Quarter 2025 Financial Results and Corporate Update Conference Call and Webcast  | 
| Date: | November 12, 2025 | 
| Time: | 4:30pm ET/ 22:30 CET | 
|   Conference Call D  ial-in  Details:  |    United States: 1-844-825-9789 Belgium: 0800 38 961 The Netherlands: 0800 94 94 506 United Kingdom: 0808 238 9064  | 
| Conference ID: | 10203872 | 
| Webcast: | 
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company's website.
About Mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based on proprietary genomic, epigenomic, exosomal and other molecular signatures and assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Waltham, Massachusetts and Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth and follow us on social media at: and|   For more information:  ... LifeSci Advisors (IR & PR) John Fraunces Managing Director Tel: +1 917 355 2395 ...  |  |
Attachment
-  
   
  mdx11.25
 
   Legal Disclaimer:
 MENAFN provides the
              information “as is” without warranty of any kind. We do not accept
              any responsibility or liability for the accuracy, content, images,
              videos, licenses, completeness, legality, or reliability of the information
              contained in this article. If you have any complaints or copyright
              issues related to this article, kindly contact the provider above.

                
                
                
                
                
                
    
                       
                       
                       
                       
                       
                       
                       
                       
                       
Comments
No comment